MYOKARDIA, INC. (NASDAQ:MYOK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective on April4, 2018, the Board of Directors of MyoKardia, Inc. (the “Company”) appointed Taylor Harris as the Company’s chief financial officer.

Prior to joining the Company and from April 2016 to April 2017, Mr.Harris, age 42, served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., a public company that markets the CoolSculpting cryolipolysis procedure. During that time, he was responsible for the global finance, accounting, tax, treasury, investor relations, and information technology functions, as well as the company’s commercial operations, including customer service, product support, and inside sales. Zeltiq was acquired by Allergan plc in April 2017. Prior to Zeltiq, Mr.Harris served as Vice President and Chief Financial Officer at Thoratec Corporation, a public company that develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients worldwide, from October 2012 until October 2015, when the company was acquired by St. Jude Medical, Inc. Mr.Harris joined Thoratec as its Senior Director of Investor Relations and Business Development in February 2010, in which capacity he was responsible for developing and executing the company’s investor relations strategy, as well as supporting the company’s strategic and business development activities. Prior to joining Thoratec, Mr.Harris worked at JPMorgan Chase& Co. for over a decade in several capacities, including as a Vice President in the firm’s Healthcare Investment Banking and Equity Research departments. Mr.Harris holds a B.A. in physics and economics from the University of North Carolina at Chapel Hill.

There are no understandings or arrangements between Mr.Harris and any other person to which he was appointed as chief financial officer of the Company, and Mr.Harris has no material interest in any transaction or proposed transaction in which the Company is or is to be a party. Mr.Harris has no family relationship with any director or executive officer of the Company.

The Company entered into an at-will employment offer letter agreement with Mr.Harris, dated March26, 2018 (the “Employment Agreement”), to which Mr.Harris would become employed as Chief Financial Officer of the Company. A copy of the Employment Agreement is filed as Exhibit 10.1 to this report on Form8-K. Effective on his start date of April4, 2018 (the “Employment Start Date”), in his position as Chief Financial Officer, Mr.Harris is entitled to receive an annual base salary of $415,000 and is eligible to receive an annual performance bonus, with a target bonus amount of 40% of his annual base salary. Mr.Harris’ base salary is subject to adjustment to the Company’s employee compensation policies in effect from time to time.

to the Employment Agreement, the Company agreed to grant Mr.Harris an option to purchase 100,000shares of the Company’s common stock under the Company’s 2015 Stock Option and Incentive Plan (the “Plan”). 25% of the option shares will vest on the first anniversary of the Employment Start Date and the balance will vest in equal monthly installments over the next 36 months, subject to Mr.Harris’ continued service to the Company through each vesting date. Also to the Employment Agreement, the Company agreed to grant Mr.Harris Restricted Stock Units (“RSUs”) for 15,000 shares of the Company’s common stock under the Plan. 25% of the RSUs will vest on the first anniversary of the Employment Start Date and the balance will vest in equal annual installments over the next three years, subject to Mr.Harris’ continued service to the Company through each vesting date.

In addition, Mr.Harris is eligible to participate in the Company’s Change in Control Policy as in effect from time to time. In accordance with the policy’s terms, if Mr.Harris’ employment is terminated without Cause (as defined in the Plan) within one year after the closing of a Sale Event (as defined in the Plan), then, subject to his execution of a severance agreement and a general release of claims, Mr.Harris will receive the following benefits: (a)full acceleration of vesting of his outstanding equity awards under the Plan (as set forth in the Plan); (b) a lump sum equal to twelve months of his then-current base salary; (c)a lump sum equal to his then-current target bonus; and (d)if he is participating in the Company group health plan immediately prior to termination and elects COBRA, a monthly cash payment for twelve months equal to the Company’s monthly premium contribution.

The foregoing summary of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the complete Employment Agreement, which is attached as Exhibit 10.1 and incorporated herein by reference.

(b)

On April4, 2018, the Company’s Board of Directors also appointed Mr.Harris as the Company’s principal financial officer and principal accounting officer, replacing Jacob Bauer in these positions, and appointed Mr.Bauer as the Company’s Chief Business Officer.

On April4, 2018, the Company issued a press release announcing Mr.Harris’ appointment as chief financial officer of the Company. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K.

The information in this Item 5.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

MyoKardia Inc Exhibit
EX-10.1 2 d562620dex101.htm EX-10.1 EX-10.1 Exhibit 10.1         333 Allerton Ave South San Francisco,…
To view the full exhibit click here

About MYOKARDIA, INC. (NASDAQ:MYOK)

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics. Its pipeline includes over four therapeutic programs for the chronic treatment of over two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Its lead product candidate, MYK-461, is an orally-administered small molecule that reduces cardiac muscle contractility leading to HCM. In preclinical models of HCM, MYK-461 has been shown to prevent and reverse disease progression and to reduce left ventricular outflow tract obstruction. It is evaluating MYK-461 in over three Phase I clinical trials, including approximately two single ascending dose (SAD) trials and over one multiple ascending dose (MAD) trial.